Evaluating the potential of polymer nanoparticles for oral delivery of paclitaxel in drug-resistant cancer

Cancer Nanotechnology

Volumn 1, Issue 1-6, 2010, Pages 29-34

  Bhardwaj, V ^a   Plumb, J A ^b   Cassidy, J ^b   Ravi Kumar, M N V ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

EPR effect; Nanoparticles; Oral drug delivery; P glycoprotein; Paclitaxel

Indexed keywords

GENOXOL; NANOPARTICLE; PACLITAXEL; POLYGLACTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; IC 50; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CELL CULTURE; OVARY TUMOR; PRIORITY JOURNAL; TUMOR MODEL; TUMOR XENOGRAFT;

EID: 79952694009     PISSN: 18686958     EISSN: 18686966     Source Type: Journal    
DOI: 10.1007/s12645-010-0004-2     Document Type: Article

References (23)

1. Bhardwaj V, Ankola D, Gupta S, Schneider M, Lehr CM, Kumar M (2009) PLGA nanoparticles stabilized with cationic surfactant: safety studies and application in oral delivery of paclitaxel to treat chemical-induced breast cancer in rat. Pharm Res 26:2495-2503
2. Cuvier C, Roblot-Treupel L, Millot JM, Lizard G, Chevillard S, Manfait M, Couvreur P, Poupon MF (1992) Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance. Biochem Pharmacol 44:509-517
3. Dantzig AH, Shepard RL, Cao J, Law KL, Ehlhardt WJ, Baughman TM, Bumol TF, Starling JJ (1996) Reversal of P-glycoprotein- mediated multidrug resistance by a potent cyclopropyldibenzo- suberane modulator, LY335979. Cancer Res 56:4171-4179
4. de Verdière AC, Dubernet C, Némati F, Soma E, Appel M, Ferté J, Bernard S, Puisieux F, Couvreur P (1997) Reversion of multidrug resistance with polyalkylcyanoacrylate nanoparticles: towards a mechanism of action. Br J Cancer 76:198-205
5. Dye D, Watkins J (1980) Suspected anaphylactic reaction to cremophor EL. Br Med J 280:1353
6. Eldridge JH, Hammond CJ, Meulbroek JA, Staas JK, Gilley RM, Tice TR (1990) Controlled vaccine release in the gut-associated lymphoid tissues: I. Orally administrated biodegradable micro- spheres target the Peyer's patches. J Control Rel 11:205-214
7. Emilienne Soma C, Dubernet C, Bentolila D, Benita S, Couvreur P (2000) Reversion of multidrug resistance by co-encapsulation of doxorubicin and cyclosporin A in polyalkylcyanoacrylate nano- particles. Biomaterials 21:1-7
8. Florence AT (1997) The oral absorption of micro-and nanoparticulates: neither exceptional nor unusual. Pharm Res 14:259-266
9. ® block copolymers for overcoming drug resistance in cancer. Adv Drug Delivery Rev 54:759-779
10. Lopes NM, Adams EG, Pitts TW, Bhuyan BK (1993) Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242
11. Maeda H (1992) The tumor blood vessel as an ideal target for macromolecular anticancer agents. J Control Rel 19:315-324
12. Mistry P, Stewart AJ, Dangerfield W, Okiji S, Liddle C, Bootle D, Plumb JA, Templeton D, Charlton P (2001) In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576. Cancer Res 61:749-758
13. Plumb JA, Milroy R, Kaye SB (1989) Effects of the pH dependence of 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide- formazan absorption on chemosensitivity determined by a novel tetrazolium-based assay. Cancer Res 49:4435-4440
14. Plumb JA, Milroy R, Kaye SB (1990) The activity of verapamil as a resistance modifier in vitro in drug resistant human tumour cell lines is not stereospecific. Biochem Pharmacol 39:787-792
15. Romsicki Y, Sharom FJ (1999) The membrane lipid environment modulates drug interactions with the P-glycoprotein multidrug transporters. Biochemistry 38:6887-6896
16. Roy SN, Horwitz SB (1985) A phosphoglycoprotein associated with taxol resistance in J774.2 cells. Cancer Res 45:3856-3863
17. Sakuma S, Hayashi M, Akashi M (2001) Design of nanoparticles composed of graft copolymers for oral peptide delivery. Adv Drug Delivery Rev 47:21-37
18. Soma CE, Dubernet C, Barratt G, Nemati F, Appel M, Benita S, Couvreur P (1999) Ability of doxorubicin-loaded nanoparticles to overcome multidrug resistance of tumor cells after their capture by macrophages. Pharm Res 16:1710-1716
19. Thierry AR, Vige D, Coughlin SS, Belli JA, Dritschilo A, Rahman A (1993) Modulation of doxorubicin resistance in multidrug- resistant cells by liposomes. FASEB J 7:572-579
20. Valle J, Armstrong A, Newman C, Alakhov V, Pietrzynski G, Brewer J, Campbell S, Corrie P, Rowinsky E, Ranson M (2010) A phase 2 study of SP1049C, doxorubicin in P-glycoprotein- targeting pluronics, in patients with advanced adenocarcinoma of the esophagus and gastroesophageal junction. Investig New Drugs. doi:10.1007/s10637-010-9399-1
21. Warren L, Jardillier J-C, Malarska A, Akeli M-G (1992) Increased accumulation of drugs in multidrug-resistant cells induced by liposomes. Cancer Res 52:3241-3245
22. Wong HL, Bendayan R, Rauth AM, Xue HY, Babakhanian K, Wu XY (2006) A mechanistic study of enhanced doxorubicin uptake and retention in multidrug resistant breast cancer cells using a polymer-lipid hybrid nanoparticle system. J Pharmacol Exp Ther 317:1372-1381
23. Workman P (2010) Guidelines for the welfare and use of animals in cancer research. Br J Cancer 102:1555-1577